SOPH stock forecast, quote, news & analysis
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research... Show more
Why SOPHiA GENETICS (SOPH) Stock Is Down -22.8% in the Last 30 Days
Key Takeaways
- SOPH shares declined roughly 22.8% over the trailing 30 days, falling from about $8.07 to near $6.23, even as revenue growth accelerated.
- The pullback erased much of a sharp summer rally, though the stock remains modestly higher over the trailing three-month period.
- Third-quarter 2026 revenue rose 25% year over year to $24.3 million on record platform volume, yet shares still sold off around results day.
- Ongoing net losses and a mid-2026 equity offering have kept investor sentiment cautious despite a reaccelerating top line.
- Liquid biopsy, U.S. market expansion, and the BioPharma business remain the company's most visible growth levers.
- For deeper valuation context and expectations, review SOPH's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading strategies approach names like SOPH.
SOPHiA GENETICS (SOPH) Company Overview and Market Position
SOPHiA GENETICS (Nasdaq: SOPH) is a Switzerland-based, AI-native healthcare technology company focused on data-driven precision medicine. Its flagship product, SOPHiA DDM™, is a cloud-native, consumption-based software-as-a-service platform that analyzes genomic and multimodal data to generate clinical insights for cancer and rare-disease care. The platform serves a global network of hospitals, laboratories, and biopharma institutions across more than 70 countries, supporting both clinical diagnostics and biopharmaceutical research and development.
Investors follow SOPH for its exposure to the intersection of artificial intelligence and healthcare, its recurring consumption-based revenue model, and its network effect, in which data flowing through the platform continually improves the underlying algorithms. The company's competitive strengths include a decentralized testing model that enables institutions to run sophisticated analyses in-house, a broad regulatory footprint, and a growing roster of strategic partnerships in liquid biopsy and companion diagnostics.
SOPHiA GENETICS (SOPH) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, SOPH shares moved from approximately $8.07 to about $6.23, a decline of roughly 22.8%. The move was not linear: the stock fell sharply through the first half of October, touching a low near $6.49 on October 19, recovered into the upper $7 range in late October, and then dropped again in early November as third-quarter results were reported.
The trailing-quarter picture is more mixed. From roughly $5.69 in early August, the stock surged to an intraday-era peak near $8.92 in late August following strong second-quarter results, before giving back much of that advance. Net of the volatility, the stock is up about 9% over the trailing three months, underscoring how much of the recent decline reflects a retracement of an earlier rally rather than a new low.
What Drove SOPH Stock Price in the Last 30 Days
The most recent 30-day period was defined by a sharp sell-off that began in early October, with the shares dropping roughly 9.5% in a single session in the first week of the month and continuing lower into mid-October. No single company-specific event clearly explains the initial leg down, which is consistent with profit-taking after a strong summer run and broader investor caution around an unprofitable, higher-multiple growth name.
Positive developments during the period failed to halt the slide. On October 8, SOPHiA GENETICS and Myriad Genetics (MYGN) announced a collaboration to advance prostate-cancer genomic instability score technology, an agreement aimed at precision-oncology applications. The shares nonetheless remained under pressure.
In early November, SOPHiA GENETICS reported third-quarter results showing revenue of $24.3 million, up 25% year over year, and a record 118,000 platform analyses, up 19%. The company guided full-year revenue toward the upper end of its $94 million to $96 million range, though it cited a partial foreign-exchange offset. Despite the strong top line, the stock fell by more than 12% in the most recent session, reflecting the market's focus on a slightly wider net loss and the absence of a full guidance raise.
What Drove SOPH Stock Performance Over the Last Quarter
The broader three-month trend was shaped by strong second-quarter results. In August, the company reported second-quarter revenue of about $23.3 million, up 27% year over year, with roughly 60% volume growth in the U.S., and raised its full-year revenue guidance to $94 million to $96 million from $92 million to $94 million. That print, combined with a completed CEO transition to Ross Muken effective July 1, powered the August rally toward the stock's recent peak.
Strategic announcements also supported the narrative over the quarter, including a companion-diagnostics collaboration with AstraZeneca (AZN), a memorandum of understanding with Memorial Sloan Kettering Cancer Center toward a precision-oncology joint venture, and the Myriad Genetics prostate-score collaboration. Offsetting these positives, a June underwritten public offering of roughly 10.5 million ordinary shares created a dilution overhang, while persistent net losses kept a lid on sentiment.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI-driven trading bots. Tickeron offers hundreds of bots that trade thousands of tickers, but only the top-performing and most relevant strategies appear in this section. The featured robots vary in strategy, timeframe, and performance metrics, giving traders a way to compare automated approaches across different market conditions. For investors looking to supplement their own analysis of names like SOPH with data-driven signals, exploring the current lineup of Trending AI Robots offers a practical starting point.
SOPH Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will focus on the company's seasonally strongest fourth quarter and any updates to full-year guidance. The most important financial milestone is the stated goal of reaching positive adjusted EBITDA in the second half of 2027, a target that would mark a meaningful inflection for a company still reporting net losses.
Operationally, the ramp of the MSK-ACCESS liquid biopsy application, U.S. market momentum, and the rollout of companion-diagnostics programs remain key catalysts. Companion-diagnostic milestone payments tied to agreements such as the AstraZeneca collaboration are expected to contribute primarily in 2027. Foreign-exchange movements, reimbursement trends, and competitive dynamics in precision oncology also bear watching, as does any further capital-raising activity following the mid-2026 offering.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for SOPH turns positive, indicating new upward trend
SOPH saw its Momentum Indicator move above the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 119 similar instances where the indicator turned positive. In 110 of the 119 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SOPH's RSI Oscillator exited the oversold zone, 17 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for SOPH just turned positive on November 09, 2026. Looking at past instances where SOPH's MACD turned positive, the stock continued to rise in 49 of 53 cases over the following month. The odds of a continued upward trend are 90%.
SOPH moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where SOPH advanced for three days, in 205 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
SOPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for SOPH crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SOPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for SOPH entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.313) is normal, around the industry mean (4.477). P/E Ratio (-6.155) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.452) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. SOPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SOPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry